CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRVO
CervoMed Inc. (CRVO) EV/Sales
As of 16 October 2026, CervoMed Inc. (CRVO) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from −1.7× (December 2024) to 20.1× (April 2024); the current reading is higher than 76% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 15.9× | — |
| FY2024 | −0.7× | — |
| FY2023 | 3.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 15.9× | 61.38% |
| Sep 2025 | 9.8× | 113.85% |
| Jun 2025 | 4.6× | (25.42%) |
| Mar 2025 | 6.2× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.0× |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.6× |
| CRVO CervoMed Inc. | 2.7× |
| EDSA Edesa Biotech, Inc. compare | 39.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)